These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29096968)

  • 1. Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view.
    Fuentes B
    Med Clin (Barc); 2018 Apr; 150(7):275-281. PubMed ID: 29096968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
    Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
    Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidiabetic drugs and stroke risk. Current evidence.
    Castilla-Guerra L; Fernandez-Moreno MDC; Leon-Jimenez D; Carmona-Nimo E
    Eur J Intern Med; 2018 Feb; 48():1-5. PubMed ID: 28939005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology.
    Fuentes B; Amaro S; Alonso de Leciñana M; Arenillas JF; Ayo-Martín O; Castellanos M; Freijo M; García-Pastor A; Gomis M; Gómez Choco M; López-Cancio E; Martínez Sánchez P; Morales A; Palacio-Portilla EJ; Rodríguez-Yáñez M; Roquer J; Segura T; Serena J; Vivancos-Mora J;
    Neurologia (Engl Ed); 2021 May; 36(4):305-323. PubMed ID: 32981775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Marso SP; Kennedy KF; House JA; McGuire DK
    Diab Vasc Dis Res; 2010 Apr; 7(2):119-30. PubMed ID: 20382775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention.
    Henry RR
    Am J Med; 1998 Jul; 105(1A):20S-26S. PubMed ID: 9707264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gender-related risk of non-fatal stroke, myocardial infarction and blindness in the type 2 diabetic patients depend on the type of treatment].
    Tron'ko MD; Khalanhot MD; Kravchenko VI; Kul'chyns'ka IaB; Hur'ianov VH; Okhrimenko NV; Neshcheret AP
    Lik Sprava; 2006; (1-2):23-7. PubMed ID: 16689088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Stroke Risk and Metformin Use in Hemodialysis Patients With Diabetes Mellitus: A Nested Case-Control Study.
    Chien LN; Chou CL; Chen HH; Kao CC; Lin YC; Wu YL; Chen JS; Chen LY; Fang TC
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29146610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits.
    Madievsky R
    Perm J; 2018; 22():18-034. PubMed ID: 30227909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin monotherapy for type 2 diabetes mellitus.
    Saenz A; Fernandez-Esteban I; Mataix A; Ausejo M; Roque M; Moher D
    Cochrane Database Syst Rev; 2005 Jul; (3):CD002966. PubMed ID: 16034881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes.
    Packer M
    Diabetes Obes Metab; 2018 May; 20(5):1089-1095. PubMed ID: 29316137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
    Ametov AS; P'ianykh OP; Chernikova NA
    Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
    Bonnet F; Scheen AJ
    Diabetes Metab; 2017 Sep; 43(4):299-313. PubMed ID: 28522196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.